TD Cowen Raises Boston Scientific Corporation (BSX) Target to $115, Reaffirms ‘Buy’ Rating Ahead of Q4 Results
We recently compiled a list of the 10 Trending AI Stocks That Analysts Are Monitoring. In this article, we are going to take ...
SG Americas Securities LLC Sells 7,529 Shares of Biohaven Ltd. (NYSE:BHVN)
SG Americas Securities LLC cut its position in Biohaven Ltd. (NYSE:BHVN – Free Report) by 45.5% during the fourth quarter, Holdings Channel.com reports. The institutional investor owned 9,001 shares ...
Sweetgreen, Inc. (NYSE:SG) Receives Consensus Rating of “Moderate Buy” from Brokerages
Shares of Sweetgreen, Inc. (NYSE:SG – Get Free Report) have been assigned a consensus recommendation of “Moderate Buy” from ...
Boot Barn Buy Rating: Optimistic Growth Projections and Margin Expansion Strategies
TD Cowen analyst Max Rakhlenko has maintained their bullish stance on BOOT stock, giving a Buy rating today.Invest with Confidence: Follow ...
Investing4d
Could Trump eliminate the capital gains tax on US crypto projects?
Despite these challenges, the crypto industry remains hopeful. Advocates believe that Trump, known for his pro-business ...
Tractor Supply Faces Investment Headwinds and Margin Pressures, But Shows Transaction Growth Potential – Hold Rating Maintained
TD Cowen analyst Max Rakhlenko has maintained their neutral stance on TSCO stock, giving a Hold rating on January 28.Invest with Confidence: ...
The Taipei Times2d
China’s economic need and soft diplomacy spur about-face on visa-free entry
It’s a dramatic change in Beijing’s approach to foreign visitors, but one that analysts say is being driven by economic need ...
The Rich Are Moving Assets Abroad. What’s Prompting the Shift.
Some wealthy Americans are motivated by the changing political landscape under President Donald Trump, or they want to ...
Friday’s analyst upgrades and downgrades
National Bank Financial analyst Vishal Shreedhar expects to see “solid” year-over-year growth from Canadian Tire Corp. Ltd. ( ...
Amgen targets $34.3B-$35.7B in 2025 revenues with strong growth in key therapeutic areas
Q4 2024 Management View Amgen highlighted its robust performance in 2024, achieving 14 products annualizing over $1 billion in sales. CEO Robert Bradway emphasized the company's resilience in ...